Bayer HealthCare Commits US-Dollar 2.5 Million in Funding to Advance Global Hemophilia Research
- Details
- Category: Bayer
Bayer HealthCare announced that it is awarding more than US-Dollar 2.5 million in funding through its Bayer Hemophilia Awards Program (BHAP). 21 individuals from 12 countries will be supported for their hemophilia research activities and clinical projects.
Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128
- Details
- Category: Novo Nordisk
Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM: NTEC) announced that Novo Nordisk has completed the initial phase 1 clinical trial with NN7128 (GlycoPEGylated factor VIIa), a long-acting version of NovoSeven® coagulation factor FVIIa (recombinant) administered intravenously.
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR
- Details
- Category: Abbott
New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) (ABT-335) combined with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater improvements than the corresponding monotherapy in treating all three key lipids - LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides.
Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for DuoCover
- Details
- Category: Bristol-Myers Squibb
The European Medicines Agency (EMEA) has been formally notified by Bristol-Myers Squibb
Pharma EEIG of its decision to withdraw its application for a centralised marketing authorisation for
the medicine DuoCover (fixed-dose combination tablets of 75 mg clopidogrel/75 mg acetylsalicylic
acid and 75 mg clopidogrel/100 mg acetylsalicylic acid).
Sanofi Pharma Bristol-Myers Squibb SNC withdraws its marketing authorisation for DuoPlavin
- Details
- Category: Sanofi
The European Medicines Agency (EMEA) has been formally notified by Sanofi Pharma Bristol-Myers Squibb SNC of its decision to withdraw its application for a centralised marketing authorisation for the medicine DuoPlavin (fixed-dose combination tablets of 75 mg clopidogrel/75 mg acetylsalicylic acid and 75 mg clopidogrel/100 mg acetylsalicylic acid).
Amgen Posts Medical Education and Foundation Grants and Donations
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) posted to the company's Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company's Web site designed to provide clear and easy access to Amgen's policies and practices.
High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients
- Details
- Category: Pfizer
Pfizer Inc announced that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27 percent in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10 mg dose of Lipitor.
More Pharma News ...
- A promising start into 2008 for Nycomed
- FivePrime and Pfizer Enter Oncology and Diabetes Collaboration
- First pre-pandemic vaccine approved to help protect against pandemic influenza
- Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
- Pfiser's List of Grants and Charitable Contributions
- Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial
- Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies